These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6861860)

  • 1. Delayed elimination of triamterene and its active metabolite in chronic renal failure.
    Knauf H; Möhrke W; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(4):453-6. PubMed ID: 6861860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.
    Gilfrich HJ; Kremer G; Möhrke W; Mutschler E; Völger KD
    Eur J Clin Pharmacol; 1983; 25(2):237-41. PubMed ID: 6628507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of triamterene.
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Clin Exp Hypertens A; 1983; 5(2):249-69. PubMed ID: 6831748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Klin Wochenschr; 1983 Sep; 61(18):883-91. PubMed ID: 6632729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene.
    Muirhead MR; Somogyi AA; Rolan PE; Bochner F
    Clin Pharmacol Ther; 1986 Oct; 40(4):400-7. PubMed ID: 3757403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered hydroxylation rate of triamterene in patients with liver cirrhosis.
    Gundert-Remy U; Müller-Herrmann R; Mutschler E; Schäfer M; Weber E
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):353-7. PubMed ID: 7118322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral triamterene disposition.
    Sörgel F; Hasegawa J; Lin ET; Williams RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):306-12. PubMed ID: 4028626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
    Williams RL; Thornhill MD; Upton RA; Blume C; Clark TS; Lin E; Benet LZ
    Clin Pharmacol Ther; 1986 Aug; 40(2):226-32. PubMed ID: 3731685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
    Loew D; Barkow D; Schuster O; Knoell HE
    Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
    Fuhr U; Kober S; Zaigler M; Mutschler E; Spahn-Langguth H
    Int J Clin Pharmacol Ther; 2005 Jul; 43(7):327-34. PubMed ID: 16035375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of triamterene and its metabolite in man.
    Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man.
    Gundert-Remy U; von Kenne D; Weber E; Geissler HE; Grebian B; Mutschler E
    Eur J Clin Pharmacol; 1979 Aug; 16(1):39-44. PubMed ID: 499298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney.
    Muirhead MR; Somogyi AA
    Drug Metab Dispos; 1991; 19(2):312-6. PubMed ID: 1676629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.
    Hoffmann KJ; Regårdh CG; Aurell M; Ervik M; Jordö L
    Clin Pharmacokinet; 1980; 5(2):181-91. PubMed ID: 7363533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triamterene kinetics and dynamics in cirrhosis.
    Villeneuve JP; Rocheleau F; Raymond G
    Clin Pharmacol Ther; 1984 Jun; 35(6):831-7. PubMed ID: 6734036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of practolol elimination in all grades of chronic renal failure.
    Kaye CM; Kumana CR; Franklin DA; Baker LR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):83-8. PubMed ID: 1165145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
    Muirhead M; Bochner F; Somogyi A
    J Pharmacol Exp Ther; 1988 Feb; 244(2):734-9. PubMed ID: 3346844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.